Is Tenaya Therapeutics, Inc. (TNYA) a Buy, Sell, or Hold?
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$0.8432 USD
-$0.02 (-2.48%)
- Volume
- 1.81M
- Average Volume
- 3.75M
- Market Capitalization
- $140.48M
- P/E Ratio
- -1.79
- Dividend Yield
- 0.00%
- Price Target
- $2.00
- Year High
- $2.35
- Year Low
- $0.53
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $5.75
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Faraz Ali |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | TNYA |
| CUSIP | 87990A106 |
| CIK | 0001858848 |
| Web | https://www.tenayatherapeutics.com |
| Phone | 650 825 6900 |
| Currency | USD |
| Employees | 70 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.10 |
| Payout Ratio | 0.00 |
| Current Ratio | 5.75 |
| Quick Ratio | 5.75 |
| Cash Ratio | 4.82 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 624.36 |
| Cash Flow | -0.42 |
| Price / Cash Flow | -2.17 |
| Price / Book | 1.21 |
Price Target and Rating
| Average Stock Price Forecast | $2.00 |
| High Stock Price Forecast | $2.00 |
| Low Stock Price Forecast | $2.00 |
| Forecast Upside/Downside | -57.84% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 6 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.59 |
| Trailing P/E Ratio | -1.79 |
| PEG Ratio | -0.02 |
| P/E Growth | -0.02 |
| Net Income | $-90.6M |
| Net Margin | -36891.11% |
| Pretax Margin | -36891.11% |
| Return on Equity | -80.56% |
| Return on Assets | -61.45% |
Financials Score
| AltmanZ Score | -4.80 |
| Piotroski Score | 2.00 |
| Working Capital | 79.78M |
| Total Assets | 135.07M |
| Ebit | -83M |
| Market Cap | 144.05M |
| Total Liabilities | 28.88M |
Poll Results
About Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Stock
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial. The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration. It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and ... validate novel gene targets for the potential treatment of cardiovascular disease. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-14 21:00:00
SOUTH SAN FRANCISCO, Calif. , July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
2026-07-14 21:00:00
SOUTH SAN FRANCISCO, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it granted stock options to purchase 1,650,000 shares of Tenaya common stock to Eric Hyllengren, its newly appointed Chief Financial Officer, and an aggregate of 187,200 shares of Tenaya common stock to two new non-executive employees in connection with the commencement of their employment.
Tenaya Therapeutics Appoints Eric Hyllengren as Chief Financial Officer
2026-06-29 08:30:00
Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise Experienced Industry Leader Brings Two Decades of Finance, Strategic and Operational Expertise
2026-06-05 17:12:54
Tenaya Therapeutics, Inc. (TNYA) Presents at Jefferies Global Healthcare Conference 2026 Prepared Remarks Transcript
2026-06-03 11:51:59
Tenaya Therapeutics, Inc. (TNYA) Discusses Interim Data from MyPEAK-1 Trial of TN-201 Gene Therapy for MYBPC3-Associated HCM Transcript
2026-06-03 07:00:00
All Evaluable Patients Achieved Improvements in Multiple Hallmarks of MYBPC3-Associated HCM Benefits Among Cohort 1 Patients Sustained as Far Out as Two Years; Cohort 2 Patients Showed Greater Symptom Relief and Improved Cardiac Function at Earlier Timepoint TN-201 Granted PRIME Designation by EMA; and Pediatric Indication Accepted into FDA's Rare Disease Evidence Principles Process Tenaya Management to Host a Webcast Conference Call to Review Results at 8:00 a.m. ET / 5:00 a.m.
2026-06-02 16:30:00
SOUTH SAN FRANCISCO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that it will report new interim data from Cohort 1 and Cohort 2 of the ongoing MyPEAK™-1 Phase 1b/2 trial of TN-201 gene therapy for adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM) on Wednesday, June 3, 2026.
Tenaya Therapeutics to Participate in the Jefferies Global Healthcare Conference 2026
2026-05-29 08:00:00
SOUTH SAN FRANCISCO, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that members of its executive team will present and participate in the upcoming Jefferies Global Healthcare Conference taking place from June 2-4, 2026, in New York, New York. Faraz Ali, Tenaya's Chief Executive Officer, will provide a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET.
Frequently Asked Questions
-
What is the current Tenaya Therapeutics, Inc. (TNYA) stock price?
-
Tenaya Therapeutics, Inc.(NASDAQ:TNYA) stock price is $0.8432 in the last trading session. During the trading session, TNYA stock reached the peak price of $2.35 while $0.532 was the lowest point it dropped to. The percentage change in TNYA stock occurred in the recent session was --2.48% while the dollar amount for the price change in TNYA stock was -$-0.02.
-
TNYA's industry and sector of operation?
-
The NASDAQ listed TNYA is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of TNYA?
-
Michelle Corral | Vice President of Investor Relationship & Corporate Communications
Faraz Ali | President, CEO, Interim Principal Financial Officer & Director
Benoit G. Bruneau | Scientific Founder
Bruce R. Conklin | Scientific Founder
Saptarsi Haldar | Scientific Founder -
How many employees does TNYA have?
-
Number of TNYA employees currently stands at 70. TNYA operates from 171 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
Link for TNYA official website?
-
Official Website of TNYA is: https://www.tenayatherapeutics.com
-
How do I contact TNYA?
-
TNYA could be contacted at phone #650 825 6900 and can also be accessed through its website. TNYA operates from 171 Oyster Point Boulevard, South San Francisco, CA 94080, US.
-
How many shares of TNYA are traded daily?
-
The average number of TNYA shares traded daily for last 3 months was 3.75M.
-
What is the market cap of TNYA currently?
-
The market value of TNYA currently stands at $140.48M with its latest stock price at $0.8432